Trial of an Ayurvedic drug in Hepatitis B cases

Clinical evaluation of Bhumyamalakyadi Ghan Vati in the management of Viral Hepatitis with special reference to Hepatitis B

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/07/034576

Enrollment

Registered

2021-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K70-K77- Diseases of liver

Interventions

Intervention1: Bhumyamalakyadi Ghanvati: Bhumyamalakyadi Ghanvati 500 mg 2BD with warm water. The follow up interval will be 1 month for 3 consecutive months after patients first visit Control Interv

Eligibility

Inclusion criteria

Inclusion criteria: HBV DNA >2000IU/ml Prothrombin time upto 18 seconds and INR upto 2 Patients diagnosed with classical features of Hepatitis B.

Exclusion criteria

Exclusion criteria: Prothrombin time >18 seconds and INR >2. Hepatitis B patients with complications like ascites,TB,portal hypertension, asthma, hepatocellular carcinoma and AIDS.

Design outcomes

Primary

Measure	Time frame
Assesment will be done on the basis of prepared proforma for assesment of subjective parameter and serological markers like HBV DNA.Timepoint: The follow up interval will be 1 month for 3 consecutive months.	—

Secondary

Measure	Time frame
Assesment of improvement in symptoms of Hepatitis B.Timepoint: The follow up interval will be 1 month for 3 consecutive months.	—

Countries

India

Contacts

Public ContactProf Rajendra Prasad

Dept.of Kayachikitsa

rajendraprasad051@gmail.com9411471910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026